Gilead Terminates Phase II Clinical Trial Of GS 9450 In Patients With Chronic Hepatitis C
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants. Patient safety is Gilead’s top priority, and the company has …

Read more on Medical News Today